126 related articles for article (PubMed ID: 1106845)
1. Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease.
Nissen NI; Hansen HH; Pedersen H; Stroyer I; Dombernowsky P; Hessellund M
Cancer Chemother Rep; 1975; 59(5):1027-9. PubMed ID: 1106845
[No Abstract] [Full Text] [Related]
2. Phase I trial of a new form of an oral administration of VP-16-213.
Lau ME; Hansen HH; Nissen NI; Pedersen H
Cancer Treat Rep; 1979 Mar; 63(3):485-7. PubMed ID: 371801
[TBL] [Abstract][Full Text] [Related]
3. Clinical study of the new podophyllotoxin derivative, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-D-glucopyranoside) (NSC-141540; VP-16-213), in solid tumors.
Felix W; Senn HJ
Cancer Chemother Rep; 1975; 59(4):737-42. PubMed ID: 1100224
[TBL] [Abstract][Full Text] [Related]
4. 4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) and 4'-demethylepipodophyllotoxin 9-(4.6-0-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: preliminary observations.
Rivera G; Avery T; Pratt C
Cancer Chemother Rep; 1975; 59(4):743-9. PubMed ID: 1100225
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of etoposide for carcinoma of the prostate.
Walther PJ; Williams SD; Troner M; Greco FA; Birch R; Einhorn LH
Cancer Treat Rep; 1986 Jun; 70(6):771-2. PubMed ID: 3524825
[TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.
Edmonson JH; Decker DG; Malkasian GD; Webb MJ; Jorgensen EO
Gynecol Oncol; 1978 Feb; 6(1):7-9. PubMed ID: 620951
[No Abstract] [Full Text] [Related]
7. Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
Gockerman JP; Bartolucci AA; Nelson MO; Silberman H; Velez-Garcia E; Stein R
Cancer Treat Rep; 1986 Jun; 70(6):801-2. PubMed ID: 3524829
[No Abstract] [Full Text] [Related]
8. [Phase II study of etoposide (NK 171) in advanced hematological malignancies].
Yoshida T; Nakanishi J; Ito K; Kobayashi S; Ohtake S; Nakamura S; Hattori K
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1579-84. PubMed ID: 6476835
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
Radice PA; Bunn PA; Ihde DC
Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
[No Abstract] [Full Text] [Related]
10. Podophyllotoxin derivative VP 16-213.
Arnold AM
Cancer Chemother Pharmacol; 1979; 3(2):71-80. PubMed ID: 389478
[TBL] [Abstract][Full Text] [Related]
11. [A phase II study of NK171 (etoposide)].
Kimura K; Niitani H
Gan To Kagaku Ryoho; 1985 Oct; 12(10):2011-7. PubMed ID: 2996442
[TBL] [Abstract][Full Text] [Related]
12. [Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group].
Suzuki K
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2772-9. PubMed ID: 3753024
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors].
Jungi WF; Senn HJ; Beckmann C; Flury R; Frei P; Holdener E
Schweiz Med Wochenschr; 1975 Oct; 105(42):1365-9. PubMed ID: 179137
[TBL] [Abstract][Full Text] [Related]
14. Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial.
Wolff SN; Birch R; Sarma P; Greco FA
Cancer Treat Rep; 1986 May; 70(5):583-7. PubMed ID: 3011257
[TBL] [Abstract][Full Text] [Related]
15. [Collaborative phase II study of etoposide (NK-171). Urological Cooperative Study Group of etoposide (NK-171)].
Gan No Rinsho; 1985 Jul; 31(8):944-52. PubMed ID: 4040986
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B.
Nissen NI; Pajak TF; Leone LA; Bloomfield CD; Kennedy BJ; Ellison RR; Silver RT; Weiss RB; Cuttner J; Falkson G; Kung F; Bergevin PR; Holland JF
Cancer; 1980 Jan; 45(2):232-5. PubMed ID: 6985831
[TBL] [Abstract][Full Text] [Related]
17. [A phase II clinical trial of oral VP 16-213 in advanced non-Hodgkin's lymphoma].
Nakada H; Ogawa M; Ingaki J; Horikoshi N; Inoue K; Usui N; Adachi K; Tada A; Yamazaki H; Mukaiyama T
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1644-8. PubMed ID: 6476837
[TBL] [Abstract][Full Text] [Related]
18. VP 16-213 in acute myelogenous leukaemia.
Smith IE; Gerken ME; Clink HM; McElwain TJ
Postgrad Med J; 1976 Feb; 52(604):66-70. PubMed ID: 772645
[TBL] [Abstract][Full Text] [Related]
19. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.
Stewart DJ; Nundy D; Maroun JA; Tetreault L; Prior J
Cancer Treat Rep; 1985 Mar; 69(3):269-73. PubMed ID: 3884152
[TBL] [Abstract][Full Text] [Related]
20. [A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].
Kado M; Oshima S; Matsui Y; Shimokata K; Hara K; Kanda T; Shima K; Takenaka S
Gan To Kagaku Ryoho; 1986 Jan; 13(1):116-21. PubMed ID: 3002282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
